文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

放射联合西妥昔单抗对前列腺癌细胞系DU145的功能与突变分析

Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145.
PubMed 文献 · Radiat Oncol · 2021-07-28

该体外研究在前列腺癌细胞系DU145与A431中分析放射联合西妥昔单抗对增殖、克隆形成与凋亡的影响。DU145中4 Gy照射使细胞数减少44%,联合西妥昔单抗后减少55%;西妥昔单抗未显著改变放射后的生长抑制或存活分数,仅见凋亡细胞比例的微小变化。未检测到RAS突变或HER2扩增,但发现TP53 c.820G>T突变。

要点

  • DU145中4 Gy照射细胞数减少44%,联合西妥昔单抗减少55%,联合未显著增敏。
  • 西妥昔单抗未显著改变放射后存活分数,仅见凋亡比例微小变化。
  • 未检出RAS突变或HER2扩增,检出TP53 c.820G>T突变。

核心结论

  • 放射可抑制DU145增殖与克隆生长并诱导凋亡,但西妥昔单抗未产生显著放射增敏效应。
  • 西妥昔单抗长期处理未诱导耐药突变。

研究设计与样本

  • 体外研究,使用前列腺癌细胞系DU145与A431。
  • 采用增殖实验、克隆形成单位实验与annexin-V凋亡实验评估放射与西妥昔单抗效应。
  • 检测放射及西妥昔单抗处理后pEGFR与pERK1/2蛋白表达变化。
  • 采用NGS分析西妥昔单抗长期处理的影响。

主要发现

  • DU145中4 Gy照射后细胞数减少44%(p=0.006),4 Gy联合西妥昔单抗后减少55%(p<0.001)。
  • DU145存活分数:2 Gy为0.69,4 Gy为0.41,6 Gy为0.15(各p<0.001)。
  • 西妥昔单抗未显著改变4 Gy照射DU145细胞的生长抑制(p>0.05)或存活分数(p>0.05),但检测到对凋亡细胞比例的微小影响。
  • 西妥昔单抗处理后western blot未检测到pEGFR与pERK1/2蛋白信号。
  • 未检测到RAS突变或HER2扩增,发现TP53基因突变c.820G>T。

关键数值与推荐

  • DU145细胞4 Gy照射后细胞数减少44%(p=0.006),4 Gy联合西妥昔单抗后减少55%(p<0.001)。
  • DU145存活分数2 Gy为0.69、4 Gy为0.41、6 Gy为0.15,各p<0.001。
  • 西妥昔单抗对4 Gy照射DU145的生长抑制与存活分数均无显著影响(p>0.05)。
  • 未检出RAS突变或HER2扩增,检出TP53 c.820G>T突变。

临床怎么用

  • 该体外结果提示西妥昔单抗联合放射在DU145中未显著增强放射效应,临床决策需结合更多证据。
  • 抗EGFR联合放疗的增敏策略仍需进一步研究明确最佳组合。

局限性

  • 研究为体外细胞系实验,结果不能直接外推至临床。
  • 西妥昔单抗的放射增敏效应未显著,仅见凋亡比例的微小变化。
  • 需进一步研究明确何种抗EGFR治疗策略组合可提高放射增敏效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epidermal Growth Factor Receptor is often overexpressed in advanced prostate carcinoma. In-vitro-studies in prostate carcinoma cell line DU145 have demonstrated increased sensibility to radiation after cetuximab treatment, but clinical data are not sufficient to date. METHODS: We analyzed effects of radiation and cetuximab in DU145 and A431 using proliferation, colony-forming-unit- and annexin-V-apoptosis-assays. Changes in protein expression of pEGFR and pERK1/2 after radiation and cetuximab treatment were analyzed. Using NGS we also investigated the impact of cetuximab long-term treatment. RESULTS: Cell counts in DU145 were reduced by 44% after 4 Gy (p = 0.006) and 55% after 4 Gy and cetuximab (p < 0.001). The surviving fraction (SF) was 0.69 after 2 Gy, 0.41 after 4 Gy and 0.15 after 6 Gy (each p < 0.001). Cetuximab treatment did not alter significantly growth reduction in 4 Gy radiated DU145 cells, p > 0.05 or SF, p > 0.05, but minor effects on apoptotic cell fraction in DU145 were detected. Using western blot, there were no detectable pEGFR and pERK1/2 protein signals after cetuximab treatment. No RAS mutation or HER2 amplification was detected, however a TP53 gen-mutation c.820G > T was found. CONCLUSIONS: Radiation inhibits cell-proliferation and colony-growth and induces apoptosis in DU145. Despite blocking MAP-Kinase-pathway using cetuximab, no significant radiation-sensitizing-effect was detected. Cetuximab treatment did not induce resistance-mutations. Further research must clarify which combination of anti-EGFR treatment strategies can increase radiation-sensitizing-effects.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Schneider R, Gademann G, Ochel HJ, et al. Functional and mutational analysis after radiation and cetuximab treatment on prostate carcinoma cell line DU145. Radiat Oncol. 2021. PMID: 34321039. doi:10.1186/s13014-021-01859-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。